Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results
11 nov. 2020 16h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for children and adults with...
Salarius Pharmaceuticals to Report Third Quarter 2020 Financial Results
04 nov. 2020 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing treatments for pediatric cancers, solid tumors and...
Salarius Pharmaceuticals to Present at BIO Investor Forum Digital
13 oct. 2020 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief...
Salarius Pharmaceuticals to Present at Upcoming Investor Conferences
10 sept. 2020 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals to Present During Virtual LD 500 Conference
27 août 2020 10h00 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today...
Salarius Pharmaceuticals Reports Business Highlights and Second Quarter 2020 Financial Results
12 août 2020 16h05 HE
|
Salarius Pharmaceuticals, Inc.
Company Closes $6.2M Public Offering and Expands Clinical Program to Include Ewing-Related Sarcomas Conference Call and Live Audio Webcast Scheduled for Today, August 12, 2020, at 4:30 p.m. ET ...
Salarius Pharmaceuticals to Report Second Quarter 2020 Financial Results
05 août 2020 09h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced...
Salarius Announces Issuance of New Patent for Seclidemstat by European Patent Office
05 août 2020 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Announces Closing of $6.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
03 août 2020 16h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.. (Nasdaq: SLRX) today announced the closing of its previously announced underwritten public offering of 5,130,390 shares of...
Salarius Announces Pricing of $5.3 Million Underwritten Public Offering
30 juil. 2020 09h22 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...